Drugs / Capecitabine tablets
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07390383 Background | Apr 2026 → May 2028 expected | high grade malignant neoplasm | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capecitabine tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07390383 ↗ |
| Route | Oral | “Oral administration” NCT07390383 ↗ |